irofulven has been researched along with Neoplasms in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.56) | 18.2507 |
| 2000's | 15 (83.33) | 29.6817 |
| 2010's | 1 (5.56) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Estes, LA; Kashinatham, A; Kelner, MJ; McMorris, TC; Staake, MD | 1 |
| Greenberg, RA; Jiang, H | 1 |
| Billups, C; Cheshire, PJ; Fouladi, M; Friedman, HS; Houghton, PJ; Leggas, M; Peterson, JK; Stewart, CF; Woo, MH | 1 |
| Baekelandt, M | 1 |
| Bailly, C; Lansiaux, A | 1 |
| Alexandre, J; Brain, EC; Cvitkovic, E; Faivre, S; Goldwasser, F; Kaci, MO; Kahatt, C; Lokiec, F; MacDonald, JR; Misset, JL; Raymond, E; Smith, SL; Yovine, A | 1 |
| Herman, TS; Macdonald, JR; Salinas, R; Trevino, AV; Waters, SJ; Woynarowska, BA; Woynarowski, JM | 1 |
| Dent, P; Grant, S | 1 |
| Gupta, N; Lee, MS; Loewenstein, J; Milam, AH; Penson, RT; Seiden, MV; Wepner, MS | 1 |
| Lokiec, F; Rezaí, K; Urien, S | 1 |
| Bernstein, M; Blaney, SM; Bomgaars, LR; Dale Weitman, S; Hershon, L; Kuhn, JG; Langevin, AM; Megason, GC; Pullen, J | 1 |
| Alexandre, J; Chieze, S; Cvitkovic, E; Faivre, S; Goldwasser, F; Hilgers, W; Kahatt, C; Lokiec, F; MacDonald, JR; Misset, JL; Raymond, E; Taamma, A; Weems, G | 1 |
| Cvitkovic, E; De Valeriola, D; Deroussent, A; Kahatt, C; Lokiec, F; Paci, A; Re, M; Rezai, K; Shah, A; Vassal, G; Waters, S; Weems, G; Weill, S | 1 |
| Alexandre, J; Bertheault-Cvitkovic, F; Cvitkovic, E; Faivre, S; Goldwasser, F; Hilgers, W; Kahatt, C; Lokiec, F; MacDonald, JR; Raymond, E; Shah, A; Shibata, S; Weems, G | 1 |
| Blatner, G; Cannon, DJ; Cheson, BD; Murgo, A | 1 |
| Baker, SD; Britten, CD; Clark, GM; Drengler, R; Eckhardt, SG; Felton, S; Hammond, LA; Hidalgo, M; Kuhn, JG; MacDonald, JR; Moczygemba, J; Rowinsky, EK; Siu, L; Smith, C; Smith, SL; Villalona-Calero, MA; Von Hoff, DD; Weitman, S | 1 |
| Alberti, D; Arzoomanian, R; Bailey, H; Binger, K; Feierabend, C; MacDonald, J; Marnocha, R; Smith, C; Smith, S; Steele, T; Thomas, JP; Tutsch, KD; Wilding, G | 1 |
| Woynarowska, BA; Woynarowski, JM | 1 |
2 review(s) available for irofulven and Neoplasms
| Article | Year |
|---|---|
Irofulven (MGI Pharma).
Topics: Animals; Antineoplastic Agents, Alkylating; Clinical Trials as Topic; Humans; Neoplasms; Sesquiterpenes; Structure-Activity Relationship | 2002 |
Preferential targeting of apoptosis in tumor versus normal cells.
Topics: Antineoplastic Agents; Apoptosis; DNA Damage; DNA, Neoplasm; Humans; Models, Biological; Neoplasm Proteins; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Oxidation-Reduction; Sesquiterpenes; Tumor Cells, Cultured | 2002 |
8 trial(s) available for irofulven and Neoplasms
| Article | Year |
|---|---|
Phase I and pharmacokinetic study of irofulven administered weekly or biweekly in advanced solid tumor patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Sesquiterpenes; Time Factors | 2004 |
Cone damage in patients receiving high-dose irofulven treatment.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Electroretinography; Female; Fluorescent Antibody Technique, Indirect; Glial Fibrillary Acidic Protein; Humans; Middle Aged; Neoplasms; Retinal Cone Photoreceptor Cells; Retinal Diseases; Rhodopsin; Sesquiterpenes; Visual Field Tests; Visual Fields | 2005 |
Pharmacokinetic modelling of 5-FU production from capecitabine--a population study in 40 adult patients with metastatic cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Capecitabine; Chromatography, High Pressure Liquid; Deoxycytidine; Dose-Response Relationship, Drug; Floxuridine; Fluorouracil; Humans; Irinotecan; Middle Aged; Models, Biological; Molecular Structure; Neoplasm Metastasis; Neoplasms; Prodrugs; Sesquiterpenes | 2005 |
Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Child, Preschool; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Maximum Tolerated Dose; Neoplasms; Sesquiterpenes | 2006 |
A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Sesquiterpenes | 2006 |
Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors.
Topics: Antineoplastic Agents, Alkylating; Carbon Radioisotopes; Chromatography, High Pressure Liquid; Feces; Female; Humans; Infusions, Intravenous; Male; Molecular Structure; Neoplasms; Sesquiterpenes; Spectrometry, Mass, Electrospray Ionization; Tissue Distribution | 2006 |
A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Sesquiterpenes; Treatment Outcome | 2007 |
Phase I clinical and pharmacokinetic trial of irofulven.
Topics: Acidosis; Aged; Anorexia; Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Fatigue; Female; Half-Life; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Sesquiterpenes; Vomiting | 2001 |
8 other study(ies) available for irofulven and Neoplasms
| Article | Year |
|---|---|
Hydroxyurea derivatives of irofulven with improved antitumor efficacy.
Topics: Acetylation; Agaricales; Animals; Antineoplastic Agents, Alkylating; Cell Line, Tumor; Humans; Hydroxyurea; Mice, Inbred BALB C; Neoplasms; Polycyclic Sesquiterpenes; Sesquiterpenes | 2016 |
Morning for Irofulven, What Could be fiNER?
Topics: Antineoplastic Agents, Alkylating; DNA Repair; Humans; Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Sesquiterpenes | 2021 |
Relation between Irofulven (MGI-114) systemic exposure and tumor response in human solid tumor xenografts.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Child; Chromatography, High Pressure Liquid; Cyclophosphamide; Dacarbazine; Dactinomycin; Disease-Free Survival; Doxorubicin; Female; Glioblastoma; Glioma; Humans; Medulloblastoma; Mice; Mice, Inbred CBA; Mice, Inbred ICR; Mice, SCID; Neoplasms; Neuroblastoma; Neuroectodermal Tumors, Primitive; Radiation Chimera; Random Allocation; Rhabdoid Tumor; Rhabdomyosarcoma, Embryonal; Sesquiterpenes; Tumor Cells, Cultured; Vincristine; Xenograft Model Antitumor Assays | 2002 |
[Perspectives on the oncologist pharmacopoeia].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Dioxoles; Indoles; Isoquinolines; Neoplasms; Organoplatinum Compounds; Protease Inhibitors; Pyrazines; Pyrroles; Quinazolines; Sesquiterpenes; Tetrahydroisoquinolines; Trabectedin | 2003 |
Cell cycle effects and induction of premitotic apoptosis by irofulven in synchronized cancer cells.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; DNA Replication; G1 Phase; Gene Expression Regulation; HeLa Cells; Humans; Mitosis; Neoplasms; Proto-Oncogene Proteins c-bcl-2; S Phase; Sesquiterpenes | 2004 |
Irofulven: resurgence for alkylating therapy in cancer?
Topics: Antineoplastic Agents, Alkylating; Apoptosis; G1 Phase; Gene Expression Regulation; Humans; Mitosis; Neoplasms; Proto-Oncogene Proteins c-bcl-2; S Phase; Sesquiterpenes | 2004 |
Clinical trials referral resource. Clinical trials of MGI-114.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Neoplasms; Sesquiterpenes | 1999 |
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Kidney Diseases; Male; Middle Aged; Nausea; Neoplasms; Sesquiterpenes; Vomiting | 2000 |